The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
BioMarin Pharmaceutical Inc (BMRN)

BioMarin Pharmaceutical is a global biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products include: Vimizim (elosulfase alpha); Naglazyme (galsulfase); Kuvan (sapropterin dihydrochloride); Palynziq (pegvaliase-pqpz); Brineura (cerliponase alfa); Voxzogo (vosoritide); and Aldurazyme (laronidase). Co.'s clinical development programs include: Valoctocogene roxaparvovec, which is an adeno associated virus (AAV5) vector drug development candidate; BMN 307, which is an AAV5 mediated gene therapy; and BMN 225, which is a small-molecule therapy.

BMRN SEC Filing Email Alerts Service

Company Name:  BioMarin Pharmaceutical Inc
Website:  www.bmrn.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding BMRN:  61
Total Market Value Held by ETFs:  $1.98B
Total Market Capitalization:  $16.55B
% of Market Cap. Held by ETFs:  11.98%
March 28, 2024    10:00 PM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree BMRN Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.36 out of 4)
50th percentile
(ranked higher than approx. 50% of all stocks covered)

Analysts' Target Price:
BMRN Stock Forecast

Based on Zacks ABR data;
powered by Xignite

BioMarin Pharmaceutical Inc (BMRN) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.